Vyne Therapeutics Inc expected to post a loss of 24  cents a share - Earnings Preview

YARROW BIOSCIENCE

28/02/2022 14:06

* Vyne Therapeutics Inc  VYNE.OQ   VYNE.O  is expected
to show a
fall in quarterly revenue when it reports  results on March 2
(estimated). 
    * The Bridgewater New Jersey-based  company is expected to
report 
a 3.8% decrease in revenue to $4.125 million from $4.29 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Vyne Therapeutics
Inc is
for a loss of 24 cents per share. For the same quarter last
year, the company reported a loss of 55 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vyne
Therapeutics
Inc is $5​, about 89.3% above​ its last closing price
of $0.54. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.32       -0.32      -0.36     Missed  -11.6
 Jun. 30 2021  -0.35       -0.35      -0.35     Met     1.1
 Mar. 31 2021  -0.39       -0.41      -0.37     Beat    9.3​
 Dec. 31 2020  -0.53       -0.54      -0.55     Missed  -2.6
 ​​Sep.        -0.68       -0.67      -0.60     Beat    10.3
 30 2020                                                
 Jun. 30 2020  -0.93       -0.99      -0.80     Beat    19.5​
 Mar. 31 2020  -2.04       -2.16      -3.80     Missed  -75.9
 Dec. 31 2019  -3.36       -3.30      -3.56     Missed  -7.7
 This summary was machine generated February 28 at 14:05 GMT. 
All figures in US dollars  unless otherwise stated